Symbols

RNA

Atrium Therapeutics·NASDAQ

--(--)

Signals Analysis

Bullish signal 4

Bearish signal 2

Consensus Rating "Buy"

Bearish Engulfing

High Gross Profit Margin

Significant Net Income Decline

Revenue Beats Expectation

EPS Beats Expectation

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About RNA

Atrium Therapeutics, Inc.

Focusing on developing a cardiac-targeted RNA delivery platform for therapies against rare inherited cardiomyopathies

Industry

Biological Technology

Established Date

09/30/2025

Listing Date

02/27/2026

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.atriumtherapeutics.com

Security Type

Common stock

Office address

10578 Science Center Drive Suite 125 San Diego California 92121

Business

Introduction

Atrium Therapeutics, Inc., incorporated under the laws of the State of Delaware on September 30, 2025, is a direct wholly-owned subsidiary of Avidity Biosciences, Inc. The company is a biopharmaceutical company that is pioneering the delivery of RNA therapies to the heart, aiming to change the standard of care for individuals with cardiomyopathy. Leveraging a proprietary RNA delivery platform originally developed at Avidity, the company combines the tissue selectivity of monoclonal antibodies with the precision of oligonucleotides to target genetic drivers of diseases that were previously untreatable with drugs. Atrium focuses on addressing gene-driven cardiomyopathy, which affects millions of people around the world, and its development pipeline includes projects targeting specific gene drivers associated with serious heart disease. Backed by solid preclinical and positive clinical data, the company is positioned to redefine the treatment paradigm in precision cardiology.

Company Financials

EPS

Revenue & Expenses

RNA has released its 2025 Q4 earnings report, with revenue of 859.00K, reflecting a YoY change of -71.11%, and net profit of -29.14M, showing a YoY change of -153.09%. The Sankey diagram below clearly presents RNA's revenue sources and cost distribution.